×
S&P 500   4,128.46 (+1.74%)
DOW   32,985.05 (+1.07%)
QQQ   306.93 (+2.54%)
AAPL   148.17 (+3.05%)
MSFT   270.94 (+1.90%)
FB   193.92 (+1.20%)
GOOGL   2,233.86 (+3.62%)
AMZN   2,263.41 (+1.88%)
TSLA   751.55 (+6.19%)
NVDA   186.16 (+4.29%)
BABA   93.22 (-1.33%)
NIO   16.38 (+2.18%)
AMD   100.94 (+2.22%)
CGC   4.88 (-12.07%)
MU   72.82 (+3.14%)
T   21.23 (-0.42%)
GE   77.70 (+0.90%)
F   13.53 (+3.13%)
DIS   108.24 (+2.49%)
AMC   13.69 (+11.94%)
PFE   53.57 (-0.78%)
PYPL   85.02 (+5.72%)
NFLX   194.09 (+1.41%)
S&P 500   4,128.46 (+1.74%)
DOW   32,985.05 (+1.07%)
QQQ   306.93 (+2.54%)
AAPL   148.17 (+3.05%)
MSFT   270.94 (+1.90%)
FB   193.92 (+1.20%)
GOOGL   2,233.86 (+3.62%)
AMZN   2,263.41 (+1.88%)
TSLA   751.55 (+6.19%)
NVDA   186.16 (+4.29%)
BABA   93.22 (-1.33%)
NIO   16.38 (+2.18%)
AMD   100.94 (+2.22%)
CGC   4.88 (-12.07%)
MU   72.82 (+3.14%)
T   21.23 (-0.42%)
GE   77.70 (+0.90%)
F   13.53 (+3.13%)
DIS   108.24 (+2.49%)
AMC   13.69 (+11.94%)
PFE   53.57 (-0.78%)
PYPL   85.02 (+5.72%)
NFLX   194.09 (+1.41%)
S&P 500   4,128.46 (+1.74%)
DOW   32,985.05 (+1.07%)
QQQ   306.93 (+2.54%)
AAPL   148.17 (+3.05%)
MSFT   270.94 (+1.90%)
FB   193.92 (+1.20%)
GOOGL   2,233.86 (+3.62%)
AMZN   2,263.41 (+1.88%)
TSLA   751.55 (+6.19%)
NVDA   186.16 (+4.29%)
BABA   93.22 (-1.33%)
NIO   16.38 (+2.18%)
AMD   100.94 (+2.22%)
CGC   4.88 (-12.07%)
MU   72.82 (+3.14%)
T   21.23 (-0.42%)
GE   77.70 (+0.90%)
F   13.53 (+3.13%)
DIS   108.24 (+2.49%)
AMC   13.69 (+11.94%)
PFE   53.57 (-0.78%)
PYPL   85.02 (+5.72%)
NFLX   194.09 (+1.41%)
S&P 500   4,128.46 (+1.74%)
DOW   32,985.05 (+1.07%)
QQQ   306.93 (+2.54%)
AAPL   148.17 (+3.05%)
MSFT   270.94 (+1.90%)
FB   193.92 (+1.20%)
GOOGL   2,233.86 (+3.62%)
AMZN   2,263.41 (+1.88%)
TSLA   751.55 (+6.19%)
NVDA   186.16 (+4.29%)
BABA   93.22 (-1.33%)
NIO   16.38 (+2.18%)
AMD   100.94 (+2.22%)
CGC   4.88 (-12.07%)
MU   72.82 (+3.14%)
T   21.23 (-0.42%)
GE   77.70 (+0.90%)
F   13.53 (+3.13%)
DIS   108.24 (+2.49%)
AMC   13.69 (+11.94%)
PFE   53.57 (-0.78%)
PYPL   85.02 (+5.72%)
NFLX   194.09 (+1.41%)
LON:AREC

Arecor Therapeutics (AREC) Share Forecast, Price & News

GBX 380
0.00 (0.00%)
(As of 05/26/2022 09:00 PM ET)
Add
Compare
Today's Range
380
380
50-Day Range
330
429
52-Week Range
222
472
Volume
4,105 shs
Average Volume
4,179 shs
Market Capitalization
£105.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive AREC News and Ratings via Email

Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Arecor Therapeutics

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Sales & Book Value

Annual Sales
£1.16 million
Cash Flow
GBX 65.80 per share
Book Value
GBX 66.60 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£105.77 million
Optionable
Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Arecor Therapeutics (LON:AREC) Frequently Asked Questions

Who are Arecor Therapeutics' key executives?
Arecor Therapeutics' management team includes the following people:
  • Dr. Sarah Jennifer Howell Ph.D., CEO & Director (Age 46)
  • Ms. Susan Day Lowther FCMA, CFO, Company Sec. & Director (Age 62)
  • Dr. Lindsey Foulkes Ph.D., Chief Operating Officer
  • Dr. Jan Jezek Ph.D., Chief Scientific Officer
What is Arecor Therapeutics' stock symbol?

Arecor Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AREC."

How do I buy shares of Arecor Therapeutics?

Shares of AREC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Arecor Therapeutics' stock price today?

One share of AREC stock can currently be purchased for approximately GBX 380.

How much money does Arecor Therapeutics make?

Arecor Therapeutics has a market capitalization of £105.77 million and generates £1.16 million in revenue each year.

How many employees does Arecor Therapeutics have?

Arecor Therapeutics employs 29 workers across the globe.

What is Arecor Therapeutics' official website?

The official website for Arecor Therapeutics is www.americanresourcescorp.com.

How can I contact Arecor Therapeutics?

The company can be reached via phone at 44 1223 426 060.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.